12 August 2021 - FDA breakthrough designation granted to CytoSorbents' DrugSorb-ATR for removal of apixaban and rivaroxaban to reduce the risk of serious bleeding in urgent cardiothoracic surgery.
CytoSorbents Corporation announced that the Company has been granted a second breakthrough device designation for its DrugSorb-ATR anti-thrombotic removal system by the U.S. FDA.